The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://joshsofb040124.blogdosaga.com/39024535/glp-3-retatrutide-a-comparative-analysis